Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers

Abstract excerpt

BACKGROUND: Mortalin is enriched in a large variety of cancers and has been shown to contribute to proliferation and migration of cancer cells in multiple ways. It has been shown to bind to p53 protein in cell cytoplasm and nucleus causing inactivation of its tumor suppressor activity in cancer cells. Several other activities of mortalin including mitochondrial biogenesis, ATP production, chaperoning,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Heat shock proteins research
• Share to PARP inhibition in cancer therapy
• Share to Signaling Pathways in Disease